Discover a groundbreaking webinar delving into developing and validating liquid chromatography-mass spectrometry (LC-MS) pharmacokinetics (PK) assays for antibody-drug conjugates (ADC). Antibody-drug conjugates are a new class of targeted drugs consisting of “antibodies, cytotoxic drugs and linkers”. The antibody-drug conjugates are designed to increase the specificity and reduce the toxicity of cytotoxic drugs by utilizing antibodies to deliver the drug specifically to target cells (e.g., tumor cells) while avoiding toxicity in healthy cells.
Understanding the PK of antibody-drug conjugates in pre-clinical and clinical studies is critical to inform dose selection and supporting their successful development. Due to the complexity of antibody-drug conjugates, there are several analytes that need to be measured to characterize ADC PK profiles, including free drugs (payloads), drug-conjugated antibodies (intact ADC) and total antibody. Amador Biosciences will share a case study demonstrating the successful development and validation of LC-MS methods for all three assays.
Join this webinar to gain insights into developing and validating LC-MS PK assays for antibody-drug conjugates and their role in advising on antibody-drug conjugates’ stability and dose selection.